Details
Stereochemistry | RACEMIC |
Molecular Formula | C11H11I3NO2.Na |
Molecular Weight | 592.9137 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CCC(CC1=C(I)C(N)=C(I)C=C1I)C([O-])=O
InChI
InChIKey=LEXZDSSHLHPSQC-UHFFFAOYSA-M
InChI=1S/C11H12I3NO2.Na/c1-2-5(11(16)17)3-6-7(12)4-8(13)10(15)9(6)14;/h4-5H,2-3,15H2,1H3,(H,16,17);/q;+1/p-1
Originator
Sources: http://www.springer.com/kr/book/9783642695179
Curator's Comment: M. Sovak. Radiocontrast Agents. (1984), p. 383. ISBN13: 9783642695179
Approval Year
Doses
Dose | Population | Adverse events |
---|---|---|
75 g single, oral Overdose |
unknown, 42 years n = 1 Health Status: unknown Condition: used for diagnosis Age Group: 42 years Sex: M Population Size: 1 Sources: |
Disc. AE: Diarrhea... AEs leading to discontinuation/dose reduction: Diarrhea (1 patient) Sources: |
3 g single, oral Recommended |
unknown, adult n = 48 Health Status: unknown Condition: used for diagnosis Age Group: adult Sex: unknown Population Size: 48 Sources: |
Other AEs: Gastrointestinal disorders... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Diarrhea | 1 patient Disc. AE |
75 g single, oral Overdose |
unknown, 42 years n = 1 Health Status: unknown Condition: used for diagnosis Age Group: 42 years Sex: M Population Size: 1 Sources: |
Gastrointestinal disorders | 39 patients | 3 g single, oral Recommended |
unknown, adult n = 48 Health Status: unknown Condition: used for diagnosis Age Group: adult Sex: unknown Population Size: 48 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Additive nephrotoxicity from roentgenographic contrast media. Its occurrence in phenazopyridine-induced acute renal failure. | 1981 May |
|
Effect of iodine or iopanoic acid on thyroid Ca2+/NADPH-dependent H2O2-generating activity and thyroperoxidase in toxic diffuse goiters. | 2002 Sep |
|
Acute decrease in circulating T3 levels enhances, but does not normalise, the GH response to GHRP-6 plus GHRH in thyrotoxicosis. | 2003 Aug |
|
Perioperative management of the thyrotoxic patient. | 2003 Jun |
|
Use of oral cholecystography agents in the treatment of hyperthyroidism of subacute thyroiditis. | 2003 Mar |
|
Light-induced hormone conversion of T4 to T3 regulates photoperiodic response of gonads in birds. | 2003 Nov 13 |
|
Is there a place for thyroidectomy in older patients with thyrotoxic storm and cardiorespiratory failure? | 2003 Oct |
|
Inhibition of drug binding to human serum albumin by cholecystographic agents. | 2003 Sep |
|
Thyroid hormones interact with glucocorticoids to affect somatotroph abundance in chicken embryonic pituitary cells in vitro. | 2003 Sep |
|
Thyroid hormone-dependent seasonality in American tree sparrows (Spizella arborea): effects of GC-1, a thyroid receptor beta-selective agonist, and of iopanoic acid, a deiodinase inhibitor. | 2004 Aug |
|
Treatment of hyperthyroidism associated with thyrotropin-secreting pituitary adenomas with iopanoic acid. | 2004 Feb |
|
Iopanoic acid in the management of neonatal Graves' disease. | 2004 Feb |
|
Expression of type II iodothyronine deiodinase marks the time that a tissue responds to thyroid hormone-induced metamorphosis in Xenopus laevis. | 2004 Feb 1 |
|
[Levothyroxine poisoning: clinical manifestations and therapeutic management]. | 2004 Jan |
|
Oral contrast-enhanced CT cholangiography--an initial experience. | 2004 Jan |
|
Rapid preparation of severe uncontrolled thyrotoxicosis due to Graves' disease with Iopanoic acid--a case report. | 2004 Jan |
|
Rapid preoperative preparation for severe hyperthyroid Graves' disease. | 2004 May |
|
Thyroid (dys)function in heart failure: is it a potential target for medical treatment? | 2005 |
|
Electrospray ionization mass spectrometry as a tool for determination of drug binding sites to human serum albumin by noncovalent interaction. | 2005 |
|
Effects of tetraiodothyronine and triiodothyronine on hamster cheek pouch microcirculation. | 2005 Apr |
|
Suppression of hypothalamic deiodinase type II activity blunts TRH mRNA decline during fasting. | 2005 Aug 29 |
|
Effect of iopanoic acid on radioiodine therapy of hyperthyroidism: long-term outcome of a randomized controlled trial. | 2005 Dec |
|
Percutaneous transcholecystic biliary interventions using gallbladder anchors: feasibility study in the swine. | 2005 Jul-Aug |
|
Thin-section multiplanar reformats from multidetector-row CT data: utility for assessment of regional tumor extent in non-small cell lung cancer. | 2005 Oct |
|
Liquid chromatography-electrospray ionization mass spectrometry for direct identification and quantification of iophenoxic acid in serum. | 2006 Feb 17 |
|
Comparison of enhancing effects of different goitrogen treatments in combination with beta-estradiol-3-benzoate for establishing a rat two-stage thyroid carcinogenesis model to detect modifying effects of estrogenic compounds. | 2006 Jan |
|
Long-lasting systemic bait markers for Eurasian badgers. | 2006 Oct |
|
Unliganded thyroid hormone receptor is essential for Xenopus laevis eye development. | 2006 Oct 18 |
|
An in vivo multiwell-based fluorescent screen for monitoring vertebrate thyroid hormone disruption. | 2007 Aug 15 |
|
Hashimoto's thyroiditis and the role of selenium. Current concepts. | 2007 Jan-Apr |
|
Combination of minimally invasive thyroid surgery and local anesthesia associated to iopanoic acid for patients with amiodarone-induced thyrotoxicosis and severe cardiac disorders: a pilot study. | 2007 Nov |
|
A fatal case of recurrent amiodarone-induced thyrotoxicosis after percutaneous tracheotomy: a case report. | 2007 Nov 13 |
|
Crystallographic analysis of human serum albumin complexed with 4Z,15E-bilirubin-IXalpha. | 2008 Aug 29 |
|
Pharmacodynamic effect of iopanoic acid on free T(3) and T(4) levels in amiodarone-induced thyrotoxicosis. | 2008 Dec |
|
[Rapid preoperative preparation with iopanoic acid in severe liver toxicity due to methimazole: anesthetic implications]. | 2008 Feb |
|
Morphological and biochemical changes in the Harderian gland of hypothyroid rats. | 2008 Feb |
|
Structural basis of GC-1 selectivity for thyroid hormone receptor isoforms. | 2008 Jan 31 |
|
Vaccination of feral pigs (Sus scrofa) using iophenoxic acid as a simulated vaccine. | 2008 Jan-Feb |
|
Amiodarone-induced thyrotoxicosis. A review. | 2008 Sep |
|
Effects of different treatments for hyperthyroidism on the hypothalamic-pituitary-adrenal axis. | 2008 Sep |
|
A thyroid hormone deiodinase inhibitor can decrease cutaneous cell proliferation in vitro. | 2009 Feb |
|
Competitive inhibition of organic anion transporting polypeptide 1c1-mediated thyroxine transport by the fenamate class of nonsteroidal antiinflammatory drugs. | 2009 Feb |
|
Effects and safety of iopanoic acid in cats administered levothyroxine. | 2009 Feb |
|
Anesthetic considerations in a patient with amiodarone-induced thyrotoxicosis. | 2010 |
|
Implication of type 3 deiodinase induction in zebrafish fin regeneration. | 2010 Aug 1 |
|
Autoimmune thyroid diseases in children. | 2010 Dec 14 |
|
Analysis by LC/ESI-MS of iophenoxic acid derivatives and evaluation as markers of oral baits to deliver pharmaceuticals to wildlife. | 2010 Jul 15 |
|
Colloid formation by drugs in simulated intestinal fluid. | 2010 May 27 |
|
Identification of iopanoic acid as substrate of type 1 deiodinase by a novel nonradioactive iodide-release assay. | 2012 May |
|
Monitoring of deiodinase deficiency based on transcriptomic responses in SH-SY5Y cells. | 2013 Jun |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1304283
Take 500 mg orally twice a day for the first 3 weeks.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
219-683-3
Created by
admin on Sat Dec 16 10:04:20 GMT 2023 , Edited by admin on Sat Dec 16 10:04:20 GMT 2023
|
PRIMARY | |||
|
m6371
Created by
admin on Sat Dec 16 10:04:20 GMT 2023 , Edited by admin on Sat Dec 16 10:04:20 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB02750MIG
Created by
admin on Sat Dec 16 10:04:20 GMT 2023 , Edited by admin on Sat Dec 16 10:04:20 GMT 2023
|
PRIMARY | |||
|
439WET4G58
Created by
admin on Sat Dec 16 10:04:20 GMT 2023 , Edited by admin on Sat Dec 16 10:04:20 GMT 2023
|
PRIMARY | |||
|
23669441
Created by
admin on Sat Dec 16 10:04:20 GMT 2023 , Edited by admin on Sat Dec 16 10:04:20 GMT 2023
|
PRIMARY | |||
|
340398
Created by
admin on Sat Dec 16 10:04:20 GMT 2023 , Edited by admin on Sat Dec 16 10:04:20 GMT 2023
|
PRIMARY | RxNorm | ||
|
DTXSID20947842
Created by
admin on Sat Dec 16 10:04:20 GMT 2023 , Edited by admin on Sat Dec 16 10:04:20 GMT 2023
|
PRIMARY | |||
|
100000086410
Created by
admin on Sat Dec 16 10:04:20 GMT 2023 , Edited by admin on Sat Dec 16 10:04:20 GMT 2023
|
PRIMARY | |||
|
138711-85-0
Created by
admin on Sat Dec 16 10:04:20 GMT 2023 , Edited by admin on Sat Dec 16 10:04:20 GMT 2023
|
SUPERSEDED | |||
|
2497-78-1
Created by
admin on Sat Dec 16 10:04:20 GMT 2023 , Edited by admin on Sat Dec 16 10:04:20 GMT 2023
|
PRIMARY |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD